DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Dasotraline
Dasotraline
Pdf/247Kb
Joel L. Young, M.D
Supported by an Educational Grant from Sunovion Pharmaceuticals Inc. Faculty
Horizon Scanning Status Report June 2019
Treatment-Resistant Attention-Deficit Hyperactivity Disorder: Clinical
Rxoutlook® 1St Quarter 2019
ADHD Investor Event Presentation
有限公司 Naphthalenes
Wednesday, June 12, 2019 4:00Pm
Full Report (PDF/8011KB)
Serotonin Transporter 5-HTT; SERT; SLC6A4
Department of Health and Human Services Division Of
Binge Eating Disorder
170 Efficacy and Safety of Dasotraline in Adults with Binge-Eating Disorder
(12) Patent Application Publication (10) Pub. No.: US 2016/0354315 A1 Li (43) Pub
Stembook 2018.Pdf
Sunovion Pharmaceuticals Inc.), Formulation: Oral ・ SEP-225289 Is a Dopamine and Norepinephrine Reuptake Inhibitor (DNRI)
ADHD: Reviewing the Causes and Evaluating Solutions
Top View
Assessment of Human Abuse Potential of Dasotraline Compared To
Adhd, Performance Enhancement, Or Cosmetic Neurology: Clinical and Ethical Issues
Attention Deficit Disorder Focus Turns to Side Effects
Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa
Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
Current and Future Nonstimulants in the Treatment of Pediatric ADHD: Monoamine Reuptake Inhibitors, Receptor Modulators, And
New Insights Into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties
Study Protocol Are Shown in Table 3 and Table 4
Hyperactivity Disorder: a Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Trial in Adults
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Curriculum Vitae
Binge Eating Disorder, Bulimia Nervosa, and Anorexia Nervosa
Drug Pipeline MONTHLY UPDATE
ADHD CASES Learning Objectives
A View Into Upcoming Specialty & Traditional Drugs
FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD
4-Feng Zhu-MS
Drug Pipeline Monthly Update